These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

844 related articles for article (PubMed ID: 25606362)

  • 81. Repeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disorders.
    Usdin K; Hayward BE; Kumari D; Lokanga RA; Sciascia N; Zhao XN
    Front Genet; 2014; 5():226. PubMed ID: 25101111
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Efficient Delivery of
    Chadman KK; Adayev T; Udayan A; Ahmed R; Dai CL; Goodman JH; Meeker H; Dolzhanskaya N; Velinov M
    Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833432
    [TBL] [Abstract][Full Text] [Related]  

  • 83. mGluR7 allosteric modulator AMN082 corrects protein synthesis and pathological phenotypes in FXS.
    Kumar V; Lee KY; Acharya A; Babik MS; Christian-Hinman CA; Rhodes JS; Tsai NP
    EMBO Mol Med; 2024 Mar; 16(3):506-522. PubMed ID: 38374465
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Fragile X syndrome: a review of clinical and molecular diagnoses.
    Ciaccio C; Fontana L; Milani D; Tabano S; Miozzo M; Esposito S
    Ital J Pediatr; 2017 Apr; 43(1):39. PubMed ID: 28420439
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Progress toward therapeutic potential for AFQ056 in Fragile X syndrome.
    Sourial M; Cheng C; Doering LC
    J Exp Pharmacol; 2013; 5():45-54. PubMed ID: 27186135
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Behavioral Phenotype of Fmr1 Knock-Out Mice during Active Phase in an Altered Light/Dark Cycle.
    Saré RM; Levine M; Smith CB
    eNeuro; 2016; 3(2):. PubMed ID: 27294193
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Gene therapy using human FMRP isoforms driven by the human
    Jiang Y; Han L; Meng J; Wang Z; Zhou Y; Yuan H; Xu H; Zhang X; Zhao Y; Lu J; Xu H; Zhang C; Zhang YW
    Mol Ther Methods Clin Dev; 2022 Dec; 27():246-258. PubMed ID: 36320413
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Fragile x syndrome.
    McLennan Y; Polussa J; Tassone F; Hagerman R
    Curr Genomics; 2011 May; 12(3):216-24. PubMed ID: 22043169
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Targeted Reactivation of
    Haenfler JM; Skariah G; Rodriguez CM; Monteiro da Rocha A; Parent JM; Smith GD; Todd PK
    Front Mol Neurosci; 2018; 11():282. PubMed ID: 30158855
    [TBL] [Abstract][Full Text] [Related]  

  • 90. FXS-Like Phenotype in Two Unrelated Patients Carrying a Methylated Premutation of the
    Fernández E; Gennaro E; Pirozzi F; Baldo C; Forzano F; Turolla L; Faravelli F; Gastaldo D; Coviello D; Grasso M; Bagni C
    Front Genet; 2018; 9():442. PubMed ID: 30450110
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Fragile X syndrome and fragile X-associated tremor ataxia syndrome.
    Hall DA; Berry-Kravis E
    Handb Clin Neurol; 2018; 147():377-391. PubMed ID: 29325626
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
    De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
    Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome.
    Cogram P; Deacon RMJ; Warner-Schmidt JL; von Schimmelmann MJ; Abrahams BS; During MJ
    Front Behav Neurosci; 2019; 13():141. PubMed ID: 31293404
    [TBL] [Abstract][Full Text] [Related]  

  • 94. From wings to whiskers to stem cells: why every model matters in fragile X syndrome research.
    Sandoval SO; Méndez-Albelo NM; Xu Z; Zhao X
    J Neurodev Disord; 2024 Jun; 16(1):30. PubMed ID: 38872088
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.
    Jacquemont S; Pacini L; Jønch AE; Cencelli G; Rozenberg I; He Y; D'Andrea L; Pedini G; Eldeeb M; Willemsen R; Gasparini F; Tassone F; Hagerman R; Gomez-Mancilla B; Bagni C
    Hum Mol Genet; 2018 Jun; 27(12):2039-2051. PubMed ID: 29590342
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Astroglial FMRP modulates synaptic signaling and behavior phenotypes in FXS mouse model.
    Jin SX; Higashimori H; Schin C; Tamashiro A; Men Y; Chiang MSR; Jarvis R; Cox D; Feig L; Yang Y
    Glia; 2021 Mar; 69(3):594-608. PubMed ID: 32970902
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Inhibition of GluN2A NMDA receptors ameliorates synaptic plasticity deficits in the Fmr1
    Lundbye CJ; Toft AKH; Banke TG
    J Physiol; 2018 Oct; 596(20):5017-5031. PubMed ID: 30132892
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cell Type-Specific mRNA Dysregulation in Hippocampal CA1 Pyramidal Neurons of the Fragile X Syndrome Mouse Model.
    Ceolin L; Bouquier N; Vitre-Boubaker J; Rialle S; Severac D; Valjent E; Perroy J; Puighermanal E
    Front Mol Neurosci; 2017; 10():340. PubMed ID: 29104533
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Increased coupling of caveolin-1 and estrogen receptor α contributes to the fragile X syndrome.
    Yang Q; Yang L; Zhang K; Guo YY; Liu SB; Wu YM; Li XQ; Song Q; Zhuo M; Zhao MG
    Ann Neurol; 2015 Apr; 77(4):618-36. PubMed ID: 25611593
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Altered Developmental Expression of the Astrocyte-Secreted Factors Hevin and SPARC in the Fragile X Mouse Model.
    Wallingford J; Scott AL; Rodrigues K; Doering LC
    Front Mol Neurosci; 2017; 10():268. PubMed ID: 28900386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.